Luigi Maione

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1689869/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Quantitative but not qualitative flavor recognition impairments in COVID-19 patients. Irish Journal of Medical Science, 2022, 191, 1759-1766.	0.8	1
2	Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2812-e2824.	1.8	6
3	Parathyroid hormone in situ measurement in patients with hyperparathyroidism: single-centre experience of 179 patients. European Journal of Endocrinology, 2022, 186, 489-501.	1.9	3
4	ldentification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene <i>ARMC5</i> in 352 unselected patients. European Journal of Endocrinology, 2022, 187, 123-134.	1.9	18
5	Second brain tumours after pituitary irradiation: lower risk than once thought. Lancet Diabetes and Endocrinology,the, 2022, 10, 552-554.	5.5	0
6	IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3644-e3653.	1.8	5
7	Cardiovascular complications of acromegaly. Annales D'Endocrinologie, 2021, 82, 206-209.	0.6	11
8	Puberty, A Sensitive Window of Hypothalamic Development and Plasticity. Endocrinology, 2021, 162, .	1.4	24
9	Endocrinological diagnosis and treatment of TSH-secreting pituitary adenomas. , 2021, , 245-260.		1
10	Compromised Volumetric Bone Density and Microarchitecture in Men With Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3312-e3326.	1.8	10
11	Central precocious puberty: Recent advances in understanding the aetiology and in the clinical approach. Clinical Endocrinology, 2021, 95, 542-555.	1.2	39
12	Impact of obesity on influenza compared to pneumonia hospitalization outcomes. Obesity Research and Clinical Practice, 2021, 15, 235-242.	0.8	2
13	Makorin RING finger protein 3 and central precocious puberty. Current Opinion in Endocrine and Metabolic Research, 2020, 14, 152-159.	0.6	16
14	Flavor identification inversely correlates with body mass index (BMI). Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1299-1305.	1.1	7
15	OR11-05 Clinical Characteristics and Reproductive Hormone Levels in 201 Men With Congenital and 479 Men With Acquired Hypogonadotropic Hypogonadism: A Single-Center Comparative Study. Journal of the Endocrine Society, 2020, 4, .	0.1	0
16	GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Human Reproduction, 2020, 35, 2312-2322.	0.4	13
17	New AARS2 Mutations in Two Siblings With Tremor, Downbeat Nystagmus, and Primary Amenorrhea: A Benign Phenotype Without Leukoencephalopathy. Movement Disorders Clinical Practice, 2020, 7, 684-687.	0.8	8
18	SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database. Journal of the Endocrine Society, 2020, 4, .	0.1	0

LUIGI MAIONE

#	Article	lF	CITATIONS
19	Influences of Age, Sex and Smoking Habit on Flavor Recognition in Healthy Population. International Journal of Environmental Research and Public Health, 2020, 17, 959.	1.2	15
20	Congenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study. European Journal of Endocrinology, 2020, 182, 185.	1.9	21
21	Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocrine Reviews, 2019, 40, 669-710.	8.9	244
22	National acromegaly registries. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101264.	2.2	65
23	The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease. Neurological Sciences, 2019, 40, 1351-1356.	0.9	11
24	Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature. Endocrine, 2019, 63, 348-360.	1.1	24
25	Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused byGNRHRmutations and women with polycystic ovary syndrome. Human Reproduction, 2019, 34, 137-147.	0.4	10
26	MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males. Journal of the Endocrine Society, 2019, 3, .	0.1	0
27	GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. European Journal of Endocrinology, 2018, 178, R55-R80.	1.9	128
28	Bone mineral density in older patients with never-treated congenital hypogonadotropic hypogonadism. Endocrine, 2018, 59, 231-233.	1.1	4
29	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. European Journal of Endocrinology, 2017, 176, 645-655.	1.9	133
30	Selenium supplementation modulates apoptotic processes in thyroid follicular cells. BioFactors, 2017, 43, 415-423.	2.6	22
31	Anti-Müllerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1102-1111.	1.8	55
32	Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. Endocrine-Related Cancer, 2017, 24, 505-518.	1.6	164
33	Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. Journal of the Endocrine Society, 2017, 1, 221-230.	0.1	25
34	Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. Journal of the Endocrine Society, 2017, 1, 1362-1371.	0.1	38
35	Reversal of congenital hypogonadotropic hypogonadism in a man with Kallmann syndrome due to <i><scp>SOX</scp>10</i> mutation. Clinical Endocrinology, 2016, 85, 988-989.	1.2	19
36	Flavor perception test: evaluation in patients with Kallmann syndrome. Endocrine, 2016, 52, 236-243.	1.1	16

LUIGI MAIONE

#	Article	IF	CITATIONS
37	Pituitary function and morphology in Fabry disease. Endocrine, 2015, 50, 483-488.	1.1	5
38	Sex Steroids, Precursors, and Metabolite Deficiencies in Men With Isolated Hypogonadotropic Hypogonadism and Panhypopituitarism: A GCMS-Based Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E292-E296.	1.8	38
39	Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. European Journal of Endocrinology, 2015, 173, 693-702.	1.9	44
40	Insulin-like Peptide 3 (INSL3) in Men With Congenital Hypogonadotropic Hypogonadism/Kallmann Syndrome and Effects of Different Modalities of Hormonal Treatment: A Single-Center Study of 281 Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E268-E275.	1.8	46
41	Impact of Successful Treatment of Acromegaly on Overnight Heart Rate Variability and Sleep Apnea. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2925-2931.	1.8	46
42	Congenital hypogonadotropic hypogonadism and Kallmann syndrome as models for studying hormonal regulation of human testicular endocrine functions. Annales D'Endocrinologie, 2014, 75, 79-87.	0.6	15
43	Computed Tomography of the Anterior Skull Base in Kallmann Syndrome Reveals Specific Ethmoid Bone Abnormalities Associated With Olfactory Bulb Defects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E537-E546.	1.8	31
44	R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism. PLoS ONE, 2013, 8, e69616.	1.1	16
45	No Evidence of a Detrimental Effect of Cabergoline Therapy on Cardiac Valves in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1714-E1719.	1.8	57
46	SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. Human Reproduction, 2012, 27, 1460-1465.	0.4	133
47	Healthy birth after testicular extraction of sperm and <scp>ICSI</scp> from an azoospermic man with mild androgen insensitivity syndrome caused by an androgen receptor partial lossâ€ofâ€function mutation. Clinical Endocrinology, 2012, 77, 593-598.	1.2	22
48	Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nature Reviews Endocrinology, 2012, 8, 172-182.	4.3	124
49	Male acquired hypogonadotropic hypogonadism: Diagnosis and treatment. Annales D'Endocrinologie, 2012, 73, 141-146.	0.6	38
50	Diagnosi e terapia dell'ipogonadismo nella sindrome di Kallmann. L Endocrinologo, 2011, 12, 8-19.	0.0	1
51	Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects ofÂdifferent modalities of hormonal treatment. Fertility and Sterility, 2011, 95, 2324-2329.e3.	0.5	30
52	Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptorl± and l². Journal of Cellular Physiology, 2011, 226, 1334-1339.	2.0	40
53	Clinical, Biological and Genetic Factors Determining the Response to Pegvisomant Therapy in Acromegaly. , 2011, , P3-297-P3-297.		0
54	Seminal anti-Mullerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. Human Reproduction, 2008, 23, 1029-1034.	0.4	41

Luigi Maione

#	Article	IF	CITATIONS
55	Homozygous mutation in the prokineticin-receptor2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: Case Report. Human Reproduction, 2008, 23, 2380-2384.	0.4	60
56	Characterization of R31C GNRH1 mutation in congenital hypogonadotropic hypogonadism. Endocrine Abstracts, 0, , .	0.0	0
57	INSL3 in 268 male patients with congenital hypogonadotropic hypogonadism (CHH): effects of different modalities of hormonal treatment. Endocrine Abstracts, 0, , .	0.0	0